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Background: Royal jelly is a widely ingested supplement for health, but its effects on humans are not well known.
The objective was to evaluate the effects of long-term royal jelly ingestion on humans.
Methods: We conducted a randomized placebo-controlled, double-blind trial. A total of 61 healthy volunteers aged
42-83 years were enrolled and were randomly divided into a royal jelly group (n = 31) and a control group (n = 30).
Three thousand mg of royal jelly (RJ) or a placebo in 100 ml liquid/day were ingested for 6 months. The primary
outcomes were changes in anthropometric measurements and biochemical indexes from baseline to 6 months
after intervention.
Results: Thirty subjects in the RJ group and 26 in the control group were included in the analysis of endpoints. In
an adjusted mean change of the variables from the baseline, significant differences between the two groups could
be found in red blood cell counts (+0.16x106 /μL for the RJ group vs. -0.01x106 /μL for the control group,
P= 0.0134), hematocrit (+0.9% vs. -0.8%, P= 0.0251), log (fasting plasma glucose) (+0.01 ± 0.01 log mg/dL vs.
+0.05 ± 0.01 log mg/dL, P= 0.0297), log (insulinogenic index) (+0.25 vs. -0.13, P= 0.0319), log
dehydroepiandrosterone sulfate (DHEA-S) (+0.08 log μg/dL vs. +0.20 log μg/dL, P = 0.0483), log testosterone (T)
(+0.12 ± 0.04 log ng/mL vs. -0.02 ± 0.05 log ng/mL, P= 0.0416), log T/DHEA-S ratio (+0.05 ± 0.05 vs. -0.23 ± 0.59,
P= 0.0015), and in one of the SF-36 subscale scores, mental health (MH) (+4 vs. -7, P= 0.0276).
Conclusions: Six-month ingestion of RJ in humans improved erythropoiesis, glucose tolerance and mental health.
Acceleration of conversion from DHEA-S to T by RJ may have been observed among these favorable effects.
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Royal jelly (RJ) is mainly secreted by the hypopharyngeal
and mandibular glands of worker honeybees (Apis
mellifera) between the sixth and twelfth days of their life [1]
and is an essential food for the development of the queen
honeybee. RJ is a complex substance containing a unique
combination of proteins (12-15%), sugars (10-12%), lipids
(3-7%), amino acids, vitamins, and minerals [2]. Compared
with the short-lived and infertile worker bees, the queen
bee, which is exclusively fed RJ, is characterized by her
extended lifespan and her well-developed gonads. There-
fore, RJ has been long- used as a supplement for nutrition,
anti-aging or infertility.* Correspondence: hmorita@gifu-u.ac.jp
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reproduction in any medium, provided the orRJ has been demonstrated to possess many pharmaco-
logical activities in experimental animals, including anti-
tumor [3], anti-oxidant [4], anti-inflammatory [5],
antibacterial [6], anti-allergic [7], anti-aging [8] and anti-
hypertensive properties [9]. In humans, its oral ingestion
improves lipoprotein metabolism and reduces serum
total cholesterol (TC) and low-density lipoprotein (LDL)
levels [10]. Lady 4, a combination of four natural com-
ponents including RJ, promoted health and well-being in
postmenopausal women [11].
RJ develops the queen bee gonads. An RJ diet
induced higher testosterone (T) content and more in-
tensive spermatogenesis in hamster testis [12] and
increased serum testosterone levels in heat stressed
male rabbits [13]. It may also modulate sex hormones
in humans. Dehydroepiandrosterone sulfate (DHEA-S),Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tential longevity marker [14,15] and may improve insu-
lin resistance [16-18]. Men with higher serum DHEA-S
had a longer life span in a Baltimore longitudinal study
of aging male humans [19]. Estradiol (E2) is more im-
portant than testosterone in the pathway to insulin re-
sistance in healthy, young postmenopausal women [20].
We conducted a randomized placebo-controlled,
double-blind trial to evaluate how RJ affects biochemical,
nutritional and glucose tolerance.
Subjects and methods
Subjects
All subjects were healthy volunteers recruited mainly
among adults living in Takayama City in Japan in May
2008. They were users of a home health care telemedi-
cine system managed by ISET Co. (Tsu, Japan). The pur-
pose, benefit and risk of this study were explained to
each subject and a written informed consent was
obtained from all the subjects. Their lifestyle habits, past
history, present illness and medicines were obtained by a
written questionnaire at the enrollment. Diabetic
patients with poor blood sugar control (HbA1c > = 7.4%)
were excluded. A subject who had undertaken a gastrec-
tomy was also excluded.Assessed for 
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Figure 1 Flow of participants through the present study.Sixty-one healthy volunteers aged 42–83 years were
enrolled in the present study (Figure 1). The subjects
were randomly divided into two groups: one was a RJ
group (n = 31) and the other was a control group
(n = 30). Randomization was performed by random num-
bers generated by a computer at ISET Co. The RJ group
took 100 ml liquid containing 3000 mg of RJ a day for
six months and the control group received the same vol-
ume and appearance of liquid without containing RJ as a
placebo for the same period. The same amount of ingre-
dients, such as fructose, citrate, vitamin B2 and several
flavors, were contained in both kinds of liquid. These
liquids were prepared by API Co., Ltd. (Gifu, Japan) and
were provided to all the participants. The trial was
approved by the Ethics Committee of Gifu University
Graduate School of Medicine (No. 20–34).
Methods
Anthropometric measurements, blood and urinary
examinations were assessed at a checkup which we held
before and after intervention for six months. Height,
weight, body mass index (BMI), systolic and diastolic
blood pressures, pulse rate and waist circumference were
measured as anthropometry. Brachial-ankle pulse wave
velocity (baPWV) and bone mineral density (BMD) at
the calcaneus were determined using a pulse pressureeligibility (n=72) 
Excluded (n=11) 
Not meeting inclusion criteria (n=3) 
Declined to participate (n=8)
Lost to follow-up (nonattendance to the final 
checkup) (n=4) 
Discontinued intervention (adverse effects) 
(n=5) 
Allocated to placebo (n=30) 
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Japan) and an ultrasound bone densitometer (CM-200;
Erk Co., Tokyo, Japan), respectively. Blood pressure,
BMD and baPWV were measured twice and the mean
values were adopted.
All blood samples were drawn between 0700 and
0800 h a.m. after an overnight fast. A 75-g oral glucose
tolerance test (OGTT) for measuring glucose and insulin
drawn before and at 30 and 120 min after oral glucose in-
gestion was performed. Additional assessments included
as follows: screening blood tests, HbA1c, plasma
homocystein and 3-methoxy-4-hydroxy-phenylglycol
(MHPG), serum cystatin C, high sensitive C-reactive
protein (hsCRP), leptin, high-molecular-weight adipo-
nectin (hmw-adiponectin), prolactin, E2, T, DHEA-S,
undercarboxylated osteocalcin (ucOC), N-telopeptides
of type I collagen (NTx) and ratio of urinary 8-
hydroxy-2’-deoxyguanosine (8-OHdG) to creatinine.
Plasma and serum was obtained by centrifuging the
blood at 1,000 x g for 15 min at 4C immediately after
drawing blood. We commissioned SRL Inc. (Tachikawa,
Japan) to measure all of the hematological variables,
serum and urinary biochemical and hormonal concentra-
tions. Homocystein and MHPG were measured by
HPLC, cystatin C by colloidal gold enhanced immuno-
assay, leptin, E2 and ucOC by RIA, hmw-adiponectin,
prolactin, T and DHEA-S by CLEIA, and hsCRP, NTx
and 8-OHdG by ELISA.
The homeostatic model assessment-insulin resistance
index (HOMA-IR), which is calculated as fasting immu-
noreactive insulin (FIRI) (μU/mL) x fasting plasma glu-
cose (FPG) (mg/dL) divided by 405, was used to assess
insulin resistance. HOMA of β-cell function index
(HOMA-B), computed as the product of 360 x FIRI (μU/
mL) divided by the value of FPG (mg/dL) minus 63, has
been proposed to be a good measure of steady state β-
cell function. Insulinogenic index (IGI), which is the ratio
of the 30-min increment in insulin level to the 30-min
increment in glucose level in the OGTT, was used as an
index of early-phase insulin secretion from β-cells. Esti-
mated glomerular filtration rate (eGFR) and non-high
density lipoprotein cholesterol (non-HDL-C) were calcu-
lated as 194 x age−0.287 x serum creatinine (CRE) −1.094
(x 0.739 if female) and TC - HDL-C, respectively.
General health status was assessed with the use of the
Japanese version of the Medical Outcomes Study 36-
Item Short-Form Health Survey (SF-36v2TM) [21,22] be-
fore and after intervention. The SF-36, a standardized
and written questionnaire, evaluates eight dimensions of
health: physical functioning (PF), role limitations due to
physical problems (RP), bodily pain (BP), general health
perception (GH), vitality (VT), social functioning (SF),
role of limitation due to emotional problems (RE) and
mental health (MH). Scores for each domain range from0 to 100. A higher score indicates better health status.
The scores were calculated by a Japanese version of the
scoring program. The SF-36v2TM and the scoring pro-
gram were obtained from the Institute for Health Out-
comes & Process Evaluation Research (Kyoto, Japan).
A target sample size of 58 participants (29 subjects per
group) was estimated to provide > =80% power at a 5%
level of significance (2-sided) to detect a 0.9 difference
in the change in hematocrit (Ht) from baseline to the
end of intervention period between the 2 groups, with
an assumption of an SD of 5.0 and allowance for a 10%
loss to follow up.Statistical analysis
Analyses were done according to intention to treat. Data
were expressed as mean ± SEM. Baseline characteristics
were compared between the RJ group and the control
group using the Fisher exact test for categorical variables
and Student’s t-test for continuous ones. Non-normally
distributed variables were log transformed for further
analysis if they were applicable. An analysis of covari-
ance (ANCOVA), adjusted for age, sex, smoking and
drinking habits, hypertension, diabetes mellitus, dyslipi-
demia, arrhythmia, history of ischemic heart disease and
apoplexy and the baseline value as covariates, was used
to compare change from baseline to 6 months after
intervention in anthropometric and biochemical vari-
ables and the SF-36 subscale scores between the RJ and
control groups. Regarding DHEA-S, T and E2, analyses
by gender were also done because the normal range of
these hormones was quite different between the sexes.
P values less than 0.05 were considered statistically sig-
nificant. SAS 9.1.3 Service Pack 4 for Windows (SAS In-
stitute Inc., Cary, NC) was used for all statistical
analyses.Results
Among the initially enrolled 61 volunteers, 3 in the RJ
group and 5 subjects in the control group quit the inges-
tion during the intervention period (Figure 1). The rea-
sons why they gave it up were abdominal fullness,
diarrhea, and dislike of the taste but the symptoms were
not severe and they recovered after discontinuance.
There was no difference in the adverse effects between
the control and RJ groups. Among the 7 subjects who
gave up the ingestion, two in the RJ group and two in
the control group underwent the final checkup and were
not excluded from the present study according to
intention to treat analysis. One subject in the control
group who ingested the placebo completely for six
months was excluded because of nonattendance to the
final checkup. Finally, 30 in the RJ group and 26 subjects
in the control group were analyzed.
Table 1 Main baseline characteristics of the subjects in
the RJ and control group
RJ Control P value
BMI (kg/m2) 22.7±0.5 22.8±0.5 0.9533
Waist circumference (cm) 86.3±1.3 84.1±1.5 0.2626
Systolic BP (mmHg) 135±3 137±4 0.7135
Diastolic BP (mmHg) 79±2 80±2 0.6125
WBC (/μL) 5090±240 5420±280 0.3652
RBC (x106/μL) 4.52±0.08 4.64±0.08 0.3049
Hb (g/dL) 14,2±0.3 14.5±0.3 0.5076
Ht (%) 44.6±0.7 46.0±0.9 0.1915
PLT (x103/μL) 193±11 211±10 0.2222
log TG (log mg/dL) 4.79±0.13 4.54±0.09 0.1128
HDL-C (mg/dL) 57±3 59±3 0.5709
LDL-C (mg/dL) 110±5 126±4 0.0186
log FPG (log mg/dL) 4.62±0.03 4.63±0.02 0.7231
log FIRI (log μIU/mL) 1.38±0.14 1.66±0.11 0.1375
log HbA1c (log %) 1.7±0.0 1.7±0.0 0.6786
log HOMA-IR -0.00±0.16 0.29±0.11 0.1399
log HOMA-B 3.66±0.13 3.90±0.12 0.2009
log IGI -0.54±0.18 -0.41±0.20 0.6309
log DHEA-S (log μg/dL) 4.22±0.10 4.46±0.13 0.1541
male 4.52±0.11 4.74±0.13 0.2044
female 3.88±0.20 4.07±0.19 0.4258
log T (log ng/mL) -0.32±0.38 0.01±0.41 0.5544
male 1.52±0.05 1.68±0.08 0.0926
female -2.41±0.25 -2.27±0.25 0.6829
log E2 (log pg/mL) 2.41±0.14 2.74±0.21 0.1948
male 3.11±0.08 3.29±0.09 0.1138
female 1.61±0.00 1.99±0.38 0.3409
log T/DHEAS -6.84±0.32 -6.74±0.34 0.8436
male -5.30±0.11 -5.35±0.16 0.7915
female -8.59±0.20 -8.64±0.13 0.8389
log E2/T -4.18±0.26 -4.18±0.30 0.9994
male -5.32±0.08 -5.30±0.08 0.8960
female -2.88±0.25 -2.65±0.31 0.5678
SF-36 subscale scores
PF 81±3 89±2 0.0393*
RP 84±4 88±4 0.4342
BP 66±5 69±4 0.5467
GH 61±3 63±3 0.5936
VT 61±3 67±3 0.1529
SF 88±3 94±2 0.0922
RE 91±3 91±3 0.9693
MH 71±3 80±3 0.0289*
Abbreviations were denoted in the text. * P< 0.05.
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smoking and drinking habits, hypertension, diabetes
mellitus, dyslipidemia, arrhythmia, history of ischemic
heart disease and stroke at baseline between the two
groups (data not shown). Among the anthropometric
and biochemical examinations, all variables were no dif-
ferent between the groups except for lower PF and MH
of SF-36 subscales in the RJ group as shown in Table 1.
In the mean change of variables from the baseline
adjusted for age, sex, smoking and drinking habits, hyper-
tension, diabetes mellitus, dyslipidemia, arrhythmia, his-
tory of ischemic heart disease and apoplexy, peripheral
red blood cell counts (RBC), Ht, log IGI, log T, log
T/DHEA-S ratio and MH of SF-36 subscales were higher
and log FPG, and log DHEA-S were lower in the RJ
group than those in the control group (Table 2). Accord-
ing to analysis by gender, the change of log T/DHEA-S
ratio in men was significantly higher in the RJ group but
that of log E2/T in both sexes was no different between
the groups. NTx, PF and MH were higher in men of the
RJ group than in those in the control one (data not
shown). Log TG and Ht were higher and log FPG was
lower in women (data not shown).
There were no significant differences in BMI, waist cir-
cumference, lipids, hepatic and renal functions, athero-
sclerotic (blood pressure, baPWV, homocystein and
hmw-adiponectin), other glycemic (log HbA1c, log
HOMA-IR, log HOMA-B and log leptin), and bone
metabolic variables (BMD, NTx, log ucOC) (data not
shown).
Discussion
The honeybee forms two female castes: the queen and
the worker. This dimorphism does not depend on gen-
etic differences but on ingestion of RJ. Recently, it has
been demonstrated that royalactin, a 57-kDa protein, in
RJ induces the differentiation of honeybee larvae into
queens through an epidermal growth factor receptor-
mediated signaling pathway, increasing body size and
ovary development [23].
RJ has been widely used as a supplemental food for
health promotions, but little effects on human beings
have been objectively shown. Only three randomized
controlled trials to investigate the effect of RJ on humans
have been published in English so far. Improvement of
lipid metabolism [10], quality of life in postmenopausal
women [11] and fertility of couples affected by astheno-
zoospermia [24] have been reported.
The present trail has shown increases in RBC and Ht as
well as improvement of glucose tolerance and mental
health. However, no apparent effect on serum lipids as
shown by Guo et al. [10] was observed. They have shown
that serum TC and LDL-C in the RJ group decreased sig-
nificantly more than those in the control group. One of
Table 2 Changes of main variables from baseline to
6 months after intervention
RJ Control P value
BMI (kg/m2) +0.1±0.2 +0.0±0.2 0.8389
Waist circumference (cm) -2.1±0.6 -2.0±0.7 0.9115
Systolic BP (mmHg) -0±3 -1±3 0.8732
Diastolic BP (mmHg) +0±2 -1±2 0.6321
WBC (/μL) +570±270 +320±300 0.5661
RBC (x106/μL) +0.16±0.04 -0.01±0.05 0.0134*
Hb (g/dL) +0.8±0.2 +0.3±0.2 0.0548
Ht (%) +0.9±0.5 -0.8±0.5 0.0251*
PLT (x103/μL) +1±+1 +1±1 0.5809
log TG (log mg/dL) +0.04±0.06 -0.05±0.07 0.3323
HDL-C (mg/dL) +2±2 -1±2 0.2586
LDL-C (mg/dL) +9±3 +4±3 0.2690
log FPG (log mg/dL) +0.01±0.01 +0.05±0.01 0.0297*
log FIRI (log μIU/mL) +0.05±0.11 +0.04±0.12 0.9486
log HbA1c (log %) -0.0±0.0 -0.0±0.0 0.9945
log HOMA-IR +0.07±0.11 +0.08±0.13 0.9296
log HOMA-B +0.02±0.10 -0.05±0.11 0.6027
log IGI +0.25±0.11 -0.13±0.12 0.0319*
log DHEA-S (log μg/dL) +0.08±0.04 +0.20±0.04 0.0483*
male +0.06±0.06 +0.22±0.07 0.1517
female +0.11±0.04 +0.17±0.05 0.4672
log T (log ng/mL) +0.12±0.04 -0.02±0.05 0.0416
male +0.06±0.03 -0.06±0.03 0.0503
female +0.24±0.10 -0.02±0.11 0.1369
log E2 (log pg/mL) -0.01±0.04 +0.04±0.04 0.3955
male +0.02±0.06 +0.07±0.06 0.6303
female -0.06±0.06 +0.03±0.07 0.3756
log T/DHEAS +0.05±0.05 -0.23±0.59 0.0015*
male -0.01±0.06 -0.27±0.06 0.0153*
female +0.12±0.10 -0.19±0.12 0.0848
log E2/T -0.11±0.06 +0.04±0.06 0.1034
male +0.01±0.07 +0.09±0.07 0.4745
female -0.28±0.11 +0.02±0.13 0.1353
SF-36 subscale scores
PF +2±1 -1±1 0.1384
RP -6±3 -4±3 0.6050
BP +0±4 -4±4 0.4701
GH +16±12 -6±14 0.2856
VT +7±3 -1±3 0.0924
SF -1±4 -6±4 0.4395
RE -3±3 -4±3 0.8287
MH +4±3 -7±3 0.0276*
Abbreviations were denoted in the text. * P< 0.05.
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lipids is smaller doses of RJ in our study. The subjects in
their RJ group had taken 6 g of RJ a day for 4 weeks, in
contrast to 3000 mg a day for 6 months in our RJ trial.
Another possibility is that the lipid lowering effect of RJ
may be transient and not last for six months.
We could not find any papers which described the ef-
fect of RJ on anemia. Most of our participants did not
have anemia and the increase in RBC and Ht was mod-
est. There was no significant change in mean corpuscu-
lar volume and mean corpuscular hemoglobin between
before and after intervention (data not shown), suggest-
ing that RJ did not promote iron metabolism or
hemoglobin synthesis but stimulated erythropoiesis or
prolonged the lifespan of erythrocytes. The most prob-
able reason is acceleration of erythropoiesis by testoster-
one which increased in serum in the present study.
Testosterone is an anabolic steroid and has been used to
treat several types of anemia.
E2 is a primary estrogen in humans and is converted
from T by aromatase located in the ovary or adipose tis-
sues. Most of our female participants were over the age
of 50 and after menopause, resulting in lower serum E2
levels in women than those in men. DHEA-S is the most
abundant androgen in human beings and is synthesized
in the adrenal. It is then converted to T through andro-
stenedione by 3β-hydroxysteroid dehydrogenase type 2
(3β-HSD2) and 17β-hydroxysteroid dehydrogenase type
3 (17β-HSD3) located in the adrenal and testis [25]. In
the present trial, less increase in DHEA-S and more in-
crease in T in the RJ group than in the control one was
observed, suggesting that RJ may have induced the con-
version of DHEA-S to T by stimulating 3β-HSD2 and/or
17β-HSD3 as shown in Figure 2. Serum T/DHEA-S and
E2/T ratios are considered to be designated activities of
3β-HSD2 and/or 17β-HSD3 and aromatase, respectively.
The changes of log T/DHEA-S ratio were significantly
higher only in the men, suggesting that RJ may induce
3β-HSD2 and/or 17β-HSD3 activity in the testis. It is
possible that RJ also could promote those enzyme activ-
ities in the ovary if the women had normal menstrual
cycles. In contrast, the changes of log E2 and log E2/T
ratios were not different, indicating that RJ may have no
action on aromatase in human beings. The enhanced
3β-HSD2 and/or 17β-HSD3 activity may result from
high antioxidant enzyme activities of RJ [26].
RJ did not improve HOMA-IR or HbA1c but FPG
and IGI were in the present study, suggesting that RJ
stimulated insulin secretion. The improvement of glu-
cose tolerance may have been brought about by a rise
of T. T replacement restores insulin action, increases
islet insulin content, and enhances insulin secretion in
rats [27]. In contrast, treatment with T in elderly men
does not improve carbohydrate tolerance or alter
DHEA             Androstenedione        T          E2 
h Improvement of erythropoiesis, 
glucose tolerance and mental health 
3 -HSD2 17 -HSD3 Aromatase
Figure 2 Acceleration of conversion from DHEA to T by six-month ingestion of RJ, resulting in improvement of erythropoiesis, glucose
tolerance and mental health.
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[28].
No significant differences in atherosclerotic and bone
metabolic variables were observed (data not shown).
The six month intervention may have been too short to
elucidate the effect on baPWV and BMD. However, no
effects on other variables, homocystein, hmw-adiponec-
tin, NTx and ucOC, may indicate that RJ has no benefi-
cial potency on atherosclerosis or bone metabolism.
Improvement of MH of SF-36 subscales was observed.
The changes of MH as well as PF were also significant
in men, suggesting that the beneficial effects on quality
of life in men may be a secondary action of T elevation.
In late onset hypogonadism patients, testosterone
replacement therapy resulted in the improvement of
six of eight domains including MH and PF in SF-36 [29].
In a stress-inducible depression-like mouse model, 10-
hydroxy-trans-2-decenoic acid, an unsaturated fatty
acid unique to RJ, protected against depression and
anxiety [30].
In the present study, we did not observe any serious
adverse effects of RJ. In the literature, several cases of
hemorrhagic colitis [31], asthma [32] and anaphylaxis
[33] by ingestion of RJ have been reported. RJ should be
considered as a causative allergen. Increased consump-
tion of RJ in health food supplements may increase inci-
dence of RJ-related allergic reactions [33].
Limitations
This study had several limitations. First, the sample size
was minimal and may have been too small for some
measures to reach statistical significance, especially in
the case of analysis by gender. Second, we do not know
the most effective dose of RJ for a human being. Larger
or smaller daily amounts of RJ may have been necessary
to produce some important effects.
Conclusion
In conclusion, six-month ingestion of RJ in humans
improved erythropoiesis, glucose tolerance and mental
health. These may be due to secondary effects of T with
acceleration of conversion from DHEA-S to T by activa-
tion of 3β-HSD2 and/or 17β-HSD3 through anti-oxidant
enzyme potential of RJ. A RCT with larger number ofsubjects will be necessary to further verify the effects of
RJ in more detail.
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